BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Junker N, Johansen JS, Andersen CB, Kristjansen PE. Expression of YKL-40 by peritumoral macrophages in human small cell lung cancer. Lung Cancer. 2005;48:223-231. [PMID: 15829322 DOI: 10.1016/j.lungcan.2004.11.011] [Cited by in Crossref: 81] [Cited by in F6Publishing: 76] [Article Influence: 4.8] [Reference Citation Analysis]
Number Citing Articles
1 Lin YS, Liu YF, Chou YE, Yang SF, Chien MH, Wu CH, Chou CH, Cheng CW, Wang PH. Correlation of chitinase 3-like 1 single nucleotide polymorphisms and haplotypes with uterine cervical cancer in Taiwanese women. PLoS One 2014;9:e104038. [PMID: 25203433 DOI: 10.1371/journal.pone.0104038] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
2 Roslind A, Balslev E, Kruse H, Stærgaard B, Horn T. Subcellular Localization of YKL-40 in Normal and Malignant Epithelial Cells of the Breast. Ultrastructural Pathology 2009;32:101-6. [DOI: 10.1080/01913120801937673] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
3 Wang D, Zhai B, Hu F, Liu C, Zhao J, Xu J. High YKL-40 serum concentration is correlated with prognosis of Chinese patients with breast cancer. PLoS One 2012;7:e51127. [PMID: 23227243 DOI: 10.1371/journal.pone.0051127] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
4 Berger M, Cooter M, Roesler AS, Chung S, Park J, Modliszewski JL, VanDusen KW, Thompson JW, Moseley A, Devinney MJ, Smani S, Hall A, Cai V, Browndyke JN, Lutz MW, Corcoran DL; Alzheimer’s Disease Neuroimaging Initiative. APOE4 Copy Number-Dependent Proteomic Changes in the Cerebrospinal Fluid. J Alzheimers Dis 2021;79:511-30. [PMID: 33337362 DOI: 10.3233/JAD-200747] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Galamb O, Wichmann B, Sipos F, Spisák S, Krenács T, Tóth K, Leiszter K, Kalmár A, Tulassay Z, Molnár B. Dysplasia-carcinoma transition specific transcripts in colonic biopsy samples. PLoS One. 2012;7:e48547. [PMID: 23155391 DOI: 10.1371/journal.pone.0048547] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis]
6 Salamon J, Hoffmann T, Elies E, Peldschus K, Johansen JS, Lüers G, Schumacher U, Wicklein D. Antibody directed against human YKL-40 increases tumor volume in a human melanoma xenograft model in scid mice. PLoS One 2014;9:e95822. [PMID: 24752554 DOI: 10.1371/journal.pone.0095822] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
7 Eurich K, Segawa M, Toei-Shimizu S, Mizoguchi E. Potential role of chitinase 3-like-1 in inflammation-associated carcinogenic changes of epithelial cells. World J Gastroenterol 2009; 15(42): 5249-5259 [PMID: 19908331 DOI: 10.3748/wjg.15.5249] [Cited by in CrossRef: 55] [Cited by in F6Publishing: 56] [Article Influence: 4.2] [Reference Citation Analysis]
8 Kzhyshkowska J, Larionova I, Liu T. YKL-39 as a Potential New Target for Anti-Angiogenic Therapy in Cancer. Front Immunol 2019;10:2930. [PMID: 32038607 DOI: 10.3389/fimmu.2019.02930] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
9 Nøjgaard C, Høst NB, Christensen IJ, Poulsen SH, Egstrup K, Price PA, Johansen JS. Serum levels of YKL-40 increases in patients with acute myocardial infarction. Coron Artery Dis 2008;19:257-63. [PMID: 18480670 DOI: 10.1097/MCA.0b013e3282f40dd5] [Cited by in Crossref: 72] [Cited by in F6Publishing: 31] [Article Influence: 5.1] [Reference Citation Analysis]
10 Peng H, Su Q, Lin ZC, Zhu XH, Peng MS, Lv ZB. Potential suppressive effects of theophylline on human rectal cancer SW480 cells in vitro by inhibiting YKL-40 expression. Oncol Lett 2018;15:7403-8. [PMID: 29731892 DOI: 10.3892/ol.2018.8220] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
11 Ku BM, Lee YK, Ryu J, Jeong JY, Choi J, Eun KM, Shin HY, Kim DG, Hwang EM, Yoo JC, Park JY, Roh GS, Kim HJ, Cho GJ, Choi WS, Paek SH, Kang SS. CHI3L1 (YKL-40) is expressed in human gliomas and regulates the invasion, growth and survival of glioma cells. Int J Cancer 2011;128:1316-26. [PMID: 20506295 DOI: 10.1002/ijc.25466] [Cited by in Crossref: 72] [Cited by in F6Publishing: 75] [Article Influence: 6.5] [Reference Citation Analysis]
12 Roslind A, Johansen JS, Christensen IJ, Kiss K, Balslev E, Nielsen DL, Bentzen J, Price PA, Andersen E. High serum levels of YKL-40 in patients with squamous cell carcinoma of the head and neck are associated with short survival. Int J Cancer. 2008;122:857-863. [PMID: 17957792 DOI: 10.1002/ijc.23152] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.1] [Reference Citation Analysis]
13 Stawerski P, Wągrowska-Danilewicz M, Stasikowska-Kanicka O, Danilewicz M. Increased tissue immunoexpression of YKL-40 protein in high grade serous ovarian cancers. Pathol Res Pract 2011;207:573-6. [PMID: 21820815 DOI: 10.1016/j.prp.2011.06.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
14 Huang K, Wu LD. YKL-40: a potential biomarker for osteoarthritis. J Int Med Res 2009;37:18-24. [PMID: 19215669 DOI: 10.1177/147323000903700102] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 2.9] [Reference Citation Analysis]
15 Kucur M, Isman FK, Balci C, Onal B, Hacibekiroglu M, Ozkan F, Ozkan A. Serum YKL-40 levels and chitotriosidase activity as potential biomarkers in primary prostate cancer and benign prostatic hyperplasia. Urol Oncol. 2008;26:47-52. [PMID: 18190830 DOI: 10.1016/j.urolonc.2007.07.020] [Cited by in Crossref: 28] [Cited by in F6Publishing: 33] [Article Influence: 2.0] [Reference Citation Analysis]
16 Roslind A, Johansen JS. YKL-40: a novel marker shared by chronic inflammation and oncogenic transformation. Methods Mol Biol 2009;511:159-84. [PMID: 19347297 DOI: 10.1007/978-1-59745-447-6_7] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 2.5] [Reference Citation Analysis]
17 Choi IK, Kim YH, Kim JS, Seo JH. High serum YKL-40 is a poor prognostic marker in patients with advanced non-small cell lung cancer. Acta Oncol. 2010;49:861-864. [PMID: 20553098 DOI: 10.3109/02841861003631503] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
18 Schmidt H, Johansen JS, Sjoegren P, Christensen IJ, Sorensen BS, Fode K, Larsen J, von der Maase H. Serum YKL-40 Predicts Relapse-Free and Overall Survival in Patients With American Joint Committee on Cancer Stage I and II Melanoma. JCO 2006;24:798-804. [DOI: 10.1200/jco.2005.03.7960] [Cited by in Crossref: 57] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
19 Gözükara İ, Özgür T, Dolapçıoğlu K, Güngören A, Karapınar OS. YKL-40 expression in abnormal invasive placenta cases. J Perinat Med 2017;45:571-5. [PMID: 27977409 DOI: 10.1515/jpm-2016-0208] [Reference Citation Analysis]
20 Xing S, Zheng X, Zeng T, Zeng MS, Zhong Q, Cao YS, Pan KL, Wei C, Hou F, Liu WL. Chitinase 3-like 1 secreted by peritumoral macrophages in esophageal squamous cell carcinoma is a favorable prognostic factor for survival. World J Gastroenterol 2017; 23(43): 7693-7704 [PMID: 29209110 DOI: 10.3748/wjg.v23.i43.7693] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
21 Henningsen KM, Nilsson B, Johansen JS, Chen X, Pehrson S, Svendsen JH. Plasma YKL-40 is elevated in patients with recurrent atrial fibrillation after catheter ablation. Inflamm Res 2010;59:463-9. [PMID: 20012147 DOI: 10.1007/s00011-009-0146-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
22 Kastrup J, Johansen JS, Winkel P, Hansen JF, Hildebrandt P, Jensen GB, Jespersen CM, Kjoller E, Kolmos HJ, Lind I, Nielsen H, Gluud C; the CLARICOR Trial Group. High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease. European Heart Journal 2009;30:1066-72. [DOI: 10.1093/eurheartj/ehp049] [Cited by in Crossref: 120] [Cited by in F6Publishing: 112] [Article Influence: 9.2] [Reference Citation Analysis]
23 Zhao T, Su Z, Li Y, Zhang X, You Q. Chitinase-3 Like-protein-1 function and its role in diseases. Signal Transduct Target Ther. 2020;5:201. [PMID: 32929074 DOI: 10.1038/s41392-020-00303-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
24 Mylin AK, Rasmussen T, Johansen JS, Knudsen LM, Nørgaard PH, Lenhoff S, Dahl IM, Johnsen HE. Serum YKL-40 concentrations in newly diagnosed multiple myeloma patients and YKL-40 expression in malignant plasma cells. Eur J Haematol. 2006;77:416-424. [PMID: 16930142 DOI: 10.1111/j.0902-4441.2006.t01-1-ejh2879.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
25 Lee CG, Dela Cruz CS, Ma B, Ahangari F, Zhou Y, Halaban R, Sznol M, Elias JA. Chitinase-like proteins in lung injury, repair, and metastasis. Proc Am Thorac Soc 2012;9:57-61. [PMID: 22550243 DOI: 10.1513/pats.201112-056MS] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
26 Ringsholt M, Høgdall EV, Johansen JS, Price PA, Christensen LH. YKL-40 protein expression in normal adult human tissues--an immunohistochemical study. J Mol Histol 2007;38:33-43. [PMID: 17242979 DOI: 10.1007/s10735-006-9075-0] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 3.1] [Reference Citation Analysis]
27 Llorens F, Thüne K, Tahir W, Kanata E, Diaz-Lucena D, Xanthopoulos K, Kovatsi E, Pleschka C, Garcia-Esparcia P, Schmitz M, Ozbay D, Correia S, Correia Â, Milosevic I, Andréoletti O, Fernández-Borges N, Vorberg IM, Glatzel M, Sklaviadis T, Torres JM, Krasemann S, Sánchez-Valle R, Ferrer I, Zerr I. YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias. Mol Neurodegener 2017;12:83. [PMID: 29126445 DOI: 10.1186/s13024-017-0226-4] [Cited by in Crossref: 67] [Cited by in F6Publishing: 66] [Article Influence: 13.4] [Reference Citation Analysis]
28 Jubinsky PT, Dickens DS, Short MK. New Roles for Mononuclear Phagocytes in Cancer Biology. Journal of Pediatric Hematology/Oncology 2008;30:584-91. [DOI: 10.1097/mph.0b013e31816e2358] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
29 Bernardi D, Padoan A, Ballin A, Sartori M, Manara R, Scienza R, Plebani M, Della Puppa A. Serum YKL-40 following resection for cerebral glioblastoma. J Neurooncol 2012;107:299-305. [PMID: 22102082 DOI: 10.1007/s11060-011-0762-7] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 2.9] [Reference Citation Analysis]
30 Shao R. YKL-40 acts as an angiogenic factor to promote tumor angiogenesis. Front Physiol 2013;4:122. [PMID: 23755018 DOI: 10.3389/fphys.2013.00122] [Cited by in Crossref: 57] [Cited by in F6Publishing: 59] [Article Influence: 6.3] [Reference Citation Analysis]
31 Wang D, Lu JG, Wang Q, Du XL, Dong R, Wang P, Zhao L, Jiang X, Yuan LJ. Increased immunohistochemical expression of YKL-40 in the spleen of patients with portal hypertension. Braz J Med Biol Res 2012;45:264-72. [PMID: 22267006 DOI: 10.1590/s0100-879x2012007500010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
32 Itik V, Kemik O, Kemik A, Dulger AC, Sümer A, Soyoral YU, Begenik H, Purisa S, Kotan C. Serum YKL-40 Levels in Patients with Gastric Cancer. Biomark Cancer 2011;3:25-30. [PMID: 24179388 DOI: 10.4137/BIC.S7154] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
33 Ma B, Akosman B, Kamle S, Lee CM, He CH, Koo JS, Lee CG, Elias JA. CHI3L1 regulates PD-L1 and anti-CHI3L1-PD-1 antibody elicits synergistic antitumor responses. J Clin Invest 2021;131:e137750. [PMID: 34720089 DOI: 10.1172/JCI137750] [Reference Citation Analysis]
34 Väänänen T, Kallio J, Vuolteenaho K, Ojala A, Luukkaala T, Hämäläinen M, Tammela T, Kellokumpu-lehtinen P, Moilanen E. High YKL-40 is associated with poor survival in patients with renal cell carcinoma: a novel independent prognostic marker. Scandinavian Journal of Urology 2017;51:367-72. [DOI: 10.1080/21681805.2017.1327885] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
35 Bonneh-Barkay D, Bissel SJ, Kofler J, Starkey A, Wang G, Wiley CA. Astrocyte and macrophage regulation of YKL-40 expression and cellular response in neuroinflammation. Brain Pathol 2012;22:530-46. [PMID: 22074331 DOI: 10.1111/j.1750-3639.2011.00550.x] [Cited by in Crossref: 77] [Cited by in F6Publishing: 79] [Article Influence: 7.0] [Reference Citation Analysis]
36 Qin W, Zhu W, Schlatter L, Miick R, Loy TS, Atasoy U, Hewett JE, Sauter ER. Increased expression of the inflammatory protein YKL-40 in precancers of the breast. Int J Cancer 2007;121:1536-42. [PMID: 17565739 DOI: 10.1002/ijc.22881] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
37 Allin KH, Bojesen SE, Johansen JS, Nordestgaard BG. Cancer risk by combined levels of YKL-40 and C-reactive protein in the general population. Br J Cancer 2012;106:199-205. [PMID: 22095223 DOI: 10.1038/bjc.2011.501] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
38 Hector A, Kormann MS, Mack I, Latzin P, Casaulta C, Kieninger E, Zhou Z, Yildirim AÖ, Bohla A, Rieber N, Kappler M, Koller B, Eber E, Eickmeier O, Zielen S, Eickelberg O, Griese M, Mall MA, Hartl D. The chitinase-like protein YKL-40 modulates cystic fibrosis lung disease. PLoS One 2011;6:e24399. [PMID: 21949714 DOI: 10.1371/journal.pone.0024399] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 2.9] [Reference Citation Analysis]
39 Richter B, Roslind A, Hesse U, Nordling J, Johansen JS, Horn T, Hansen AB. YKL-40 and mast cells are associated with detrusor fibrosis in patients diagnosed with bladder pain syndrome/interstitial cystitis according to the 2008 criteria of the European Society for the Study of Interstitial Cystitis. Histopathology 2010;57:371-83. [PMID: 20840668 DOI: 10.1111/j.1365-2559.2010.03640.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
40 Thöm I, Andritzky B, Schuch G, Burkholder I, Edler L, Johansen JS, Bokemeyer C, Schumacher U, Laack E. Elevated pretreatment serum concentration of YKL-40-An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer. Cancer 2010;116:4114-21. [PMID: 20564116 DOI: 10.1002/cncr.25196] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 3.3] [Reference Citation Analysis]
41 Johansen JS, Bojesen SE, Mylin AK, Frikke-schmidt R, Price PA, Nordestgaard BG. Elevated Plasma YKL-40 Predicts Increased Risk of Gastrointestinal Cancer and Decreased Survival After Any Cancer Diagnosis in the General Population. JCO 2009;27:572-8. [DOI: 10.1200/jco.2008.18.8367] [Cited by in Crossref: 63] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
42 Pouyafar A, Heydarabad MZ, Mahboob S, Mokhtarzadeh A, Rahbarghazi R. Angiogenic potential of YKL-40 in the dynamics of tumor niche. Biomed Pharmacother 2018;100:478-85. [PMID: 29477911 DOI: 10.1016/j.biopha.2018.02.050] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
43 Ober C, Chupp GL. The chitinase and chitinase-like proteins: a review of genetic and functional studies in asthma and immune-mediated diseases. Curr Opin Allergy Clin Immunol 2009;9:401-8. [PMID: 19644363 DOI: 10.1097/ACI.0b013e3283306533] [Cited by in Crossref: 72] [Cited by in F6Publishing: 48] [Article Influence: 5.5] [Reference Citation Analysis]
44 Coffman FD. Chitinase 3-Like-1 (CHI3L1): a putative disease marker at the interface of proteomics and glycomics. Crit Rev Clin Lab Sci. 2008;45:531-562. [PMID: 19003601 DOI: 10.1080/10408360802334743] [Cited by in Crossref: 77] [Cited by in F6Publishing: 80] [Article Influence: 5.9] [Reference Citation Analysis]
45 Long X, Hu H, Li S, Chen M, Cai J, Song B. Hippocampal YKL-40 expression in rats after status epilepticus. Epilepsy Research 2016;125:52-7. [DOI: 10.1016/j.eplepsyres.2016.05.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
46 Bjørnbak C, Brøchner CB, Larsen LA, Johansen JS, Møllgård K. Brain barriers and a subpopulation of astroglial progenitors of developing human forebrain are immunostained for the glycoprotein YKL-40. J Histochem Cytochem 2014;62:369-88. [PMID: 24595665 DOI: 10.1369/0022155414528514] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
47 Jian J, Chen Y, Liberti R, Fu W, Hu W, Saunders-Pullman R, Pastores GM, Chen Y, Sun Y, Grabowski GA, Liu CJ. Chitinase-3-like Protein 1: A Progranulin Downstream Molecule and Potential Biomarker for Gaucher Disease. EBioMedicine 2018;28:251-60. [PMID: 29396296 DOI: 10.1016/j.ebiom.2018.01.022] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
48 Johansen JS, Jensen BV, Roslind A, Price PA. Is YKL-40 a new therapeutic target in cancer? Expert Opinion on Therapeutic Targets 2007;11:219-34. [DOI: 10.1517/14728222.11.2.219] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 2.5] [Reference Citation Analysis]
49 Wynn TA, Barron L. Macrophages: master regulators of inflammation and fibrosis. Semin Liver Dis. 2010;30:245-257. [PMID: 20665377 DOI: 10.1055/s-0030-1255354] [Cited by in Crossref: 778] [Cited by in F6Publishing: 760] [Article Influence: 64.8] [Reference Citation Analysis]
50 Schmidt H, Johansen JS, Gehl J, Geertsen PF, Fode K, von der Maase H. Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma. Cancer. 2006;106:1130-1139. [PMID: 16456816 DOI: 10.1002/cncr.21678] [Cited by in Crossref: 86] [Cited by in F6Publishing: 79] [Article Influence: 5.4] [Reference Citation Analysis]
51 Roslind A, Johansen JS, Junker N, Nielsen DL, Dzaferi H, Price PA, Balslev E. YKL-40 expression in benign and malignant lesions of the breast: a methodologic study. Appl Immunohistochem Mol Morphol 2007;15:371-81. [PMID: 18091378 DOI: 10.1097/01.pai.0000213146.77772.6a] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
52 Lee CG, Da Silva CA, Dela Cruz CS, Ahangari F, Ma B, Kang MJ, He CH, Takyar S, Elias JA. Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodeling, and injury. Annu Rev Physiol. 2011;73:479-501. [PMID: 21054166 DOI: 10.1146/annurev-physiol-012110-142250] [Cited by in Crossref: 471] [Cited by in F6Publishing: 471] [Article Influence: 42.8] [Reference Citation Analysis]
53 Jefri M, Huang YN, Huang WC, Tai CS, Chen WL. YKL-40 regulated epithelial-mesenchymal transition and migration/invasion enhancement in non-small cell lung cancer. BMC Cancer 2015;15:590. [PMID: 26275425 DOI: 10.1186/s12885-015-1592-3] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 5.1] [Reference Citation Analysis]
54 Musumeci M, Caruso V, Medulla E, Torrisi V, Migale R, Angeletti S, Musumeci S. Serum YKL-40 levels and chitotriosidase activity in patients with beta-thalassemia major. Dis Markers 2014;2014:965971. [PMID: 24808626 DOI: 10.1155/2014/965971] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
55 Hamilton G, Rath B. Circulating tumor cell interactions with macrophages: implications for biology and treatment. Transl Lung Cancer Res 2017;6:418-30. [PMID: 28904886 DOI: 10.21037/tlcr.2017.07.04] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
56 Høgdall EV, Ringsholt M, Høgdall CK, Christensen IJ, Johansen JS, Kjaer SK, Blaakaer J, Ostenfeld-Møller L, Price PA, Christensen LH. YKL-40 tissue expression and plasma levels in patients with ovarian cancer. BMC Cancer 2009;9:8. [PMID: 19134206 DOI: 10.1186/1471-2407-9-8] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 3.3] [Reference Citation Analysis]
57 Yan J, Shen P, Zheng J, Liu M. Clinical correlation between serum YKL-40 protein level and recurrence of non-muscle invasive bladder cancer. Ann Transl Med 2015;3:354. [PMID: 26807409 DOI: 10.3978/j.issn.2305-5839.2015.11.22] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
58 Komi DE, Kazemi T, Bussink AP. New Insights Into the Relationship Between Chitinase-3-Like-1 and Asthma. Curr Allergy Asthma Rep 2016;16:57. [PMID: 27438466 DOI: 10.1007/s11882-016-0637-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
59 Hamilton G, Rath B, Ulsperger E. How to target small cell lung cancer. Oncoscience 2015;2:684-92. [PMID: 26425658 DOI: 10.18632/oncoscience.212] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
60 Zhu C, Kros JM, Cheng C, Mustafa D. The contribution of tumor-associated macrophages in glioma neo-angiogenesis and implications for anti-angiogenic strategies. Neuro Oncol 2017;19:1435-46. [PMID: 28575312 DOI: 10.1093/neuonc/nox081] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 12.8] [Reference Citation Analysis]
61 Noda Y, Kawaguchi T, Korenaga M, Yoshio S, Komukai S, Nakano M, Niizeki T, Koga H, Kawaguchi A, Kanto T, Torimura T. High serum interleukin-34 level is a predictor of poor prognosis in patients with non-viral hepatocellular carcinoma. Hepatol Res 2019;49:1046-53. [PMID: 30993774 DOI: 10.1111/hepr.13350] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
62 Duraković N, Krečak I, Perić Z, Milošević M, Desnica L, Pulanić D, Pusic I, Kušec V, Vrhovac R, Pavletic SZ, Nemet D. Glycoprotein YKL-40: a novel biomarker of chronic graft-vs-host disease activity and severity? Croat Med J 2016;57:239-46. [PMID: 27374825 DOI: 10.3325/cmj.2016.57.239] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
63 Johansen JS, Pedersen AN, Schroll M, Jørgensen T, Pedersen BK, Bruunsgaard H. High serum YKL-40 level in a cohort of octogenarians is associated with increased risk of all-cause mortality. Clin Exp Immunol 2008;151:260-6. [PMID: 18070151 DOI: 10.1111/j.1365-2249.2007.03561.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 37] [Article Influence: 2.1] [Reference Citation Analysis]
64 Mitsuhashi A, Matsui H, Usui H, Nagai Y, Tate S, Unno Y, Hirashiki K, Seki K, Shozu M. Serum YKL-40 as a marker for cervical adenocarcinoma. Ann Oncol. 2009;20:71-77. [PMID: 18723551 DOI: 10.1093/annonc/mdn552] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 2.6] [Reference Citation Analysis]
65 Kzhyshkowska J, Yin S, Liu T, Riabov V, Mitrofanova I. Role of chitinase-like proteins in cancer. Biol Chem 2016;397:231-47. [PMID: 26733160 DOI: 10.1515/hsz-2015-0269] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 9.0] [Reference Citation Analysis]
66 Thongsom S, Chaocharoen W, Silsirivanit A, Wongkham S, Sripa B, Choe H, Suginta W, Talabnin C. YKL-40/chitinase-3-like protein 1 is associated with poor prognosis and promotes cell growth and migration of cholangiocarcinoma. Tumour Biol. 2016;37:9451-9463. [PMID: 26781979 DOI: 10.1007/s13277-016-4838-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
67 Salah R, Michaud P, Mati F, Harrat Z, Lounici H, Abdi N, Drouiche N, Mameri N. Anticancer activity of chemically prepared shrimp low molecular weight chitin evaluation with the human monocyte leukaemia cell line, THP-1. International Journal of Biological Macromolecules 2013;52:333-9. [DOI: 10.1016/j.ijbiomac.2012.10.009] [Cited by in Crossref: 95] [Cited by in F6Publishing: 67] [Article Influence: 10.6] [Reference Citation Analysis]
68 Medic S, Pearce RL, Heenan PJ, Ziman M. Molecular markers of circulating melanoma cells. Pigment Cell Res 2007;20:80-91. [PMID: 17371435 DOI: 10.1111/j.1600-0749.2006.00356.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
69 Gunay AE, Karaman I, Karaman ZF, Kocer D, Dogan S, Argun AS. Relationship between Serum YKL-40 Level and Forearm Arterial Patency after Repair. Ann Vasc Surg 2021;74:301-5. [PMID: 33508452 DOI: 10.1016/j.avsg.2020.12.018] [Reference Citation Analysis]
70 Lee CG, Elias JA. Role of breast regression protein-39/YKL-40 in asthma and allergic responses. Allergy Asthma Immunol Res 2010;2:20-7. [PMID: 20224674 DOI: 10.4168/aair.2010.2.1.20] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 3.9] [Reference Citation Analysis]
71 Kido J, Bando Y, Bando M, Kajiura Y, Hiroshima Y, Inagaki Y, Murata H, Ikuta T, Kido R, Naruishi K, Funaki M, Nagata T. YKL-40 level in gingival crevicular fluid from patients with periodontitis and type 2 diabetes. Oral Dis. 2015;21:667-673. [PMID: 25740558 DOI: 10.1111/odi.12334] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
72 Yu JE, Yeo IJ, Son DJ, Yun J, Han SB, Hong JT. Anti-Chi3L1 antibody suppresses lung tumor growth and metastasis through inhibition of M2 polarization. Mol Oncol 2021. [PMID: 34861103 DOI: 10.1002/1878-0261.13152] [Reference Citation Analysis]
73 Johansen JS, Schultz NA, Jensen BV. Plasma YKL-40: a potential new cancer biomarker? Future Oncol 2009;5:1065-82. [PMID: 19792974 DOI: 10.2217/fon.09.66] [Cited by in Crossref: 96] [Cited by in F6Publishing: 106] [Article Influence: 7.4] [Reference Citation Analysis]
74 Schultz NA, Johansen JS. YKL-40-A Protein in the Field of Translational Medicine: A Role as a Biomarker in Cancer Patients? Cancers (Basel) 2010;2:1453-91. [PMID: 24281168 DOI: 10.3390/cancers2031453] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 3.3] [Reference Citation Analysis]
75 Elhabak DM, Abdel Halim WA. YKL-40 A Sensitive Biomarker for Early Androgenetic Alopecia and Early Hidden Metabolic Syndrome. Int J Trichology 2020;12:49-55. [PMID: 32684675 DOI: 10.4103/ijt.ijt_100_19] [Reference Citation Analysis]
76 Roslind A, Knoop AS, Jensen MB, Johansen JS, Nielsen DL, Price PA, Balslev E. YKL-40 protein expression is not a prognostic marker in patients with primary breast cancer. Breast Cancer Res Treat 2008;112:275-85. [PMID: 18157633 DOI: 10.1007/s10549-007-9870-7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.5] [Reference Citation Analysis]
77 He B, Wang L, Wang J, Li G, Zhang S. Positive selection of three chitinase genes of the family 18 of glycoside hydrolases in mammals. Biologia 2009;64:819-25. [DOI: 10.2478/s11756-009-0117-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
78 Hamilton G, Rath B. Smoking, inflammation and small cell lung cancer: recent developments. Wien Med Wochenschr 2015;165:379-86. [PMID: 26289596 DOI: 10.1007/s10354-015-0381-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]